Boston’s Empower leadless pacemaker demonstrates “excellent overall clinical performance” in MODULAR ATP study Posted on September 26th, 2024 by LEADconnection Post navigation Previous: LBBAP limits hospital readmissions after TAVRNext: APPRAISE ATP Highlights the Trade-offs of Antitachycardia Pacing
LBBAP limits hospital readmissions after TAVR Posted on September 20th, 2024 by LEADconnection Post navigation Previous: FDA approves Boston Scientific leads for left bundle branch area pacingNext: Boston’s Empower leadless pacemaker demonstrates “excellent overall clinical performance” in MODULAR ATP study
FDA approves Boston Scientific leads for left bundle branch area pacing Posted on September 18th, 2024 by LEADconnection Post navigation Previous: Lumenless and Stylet-Driven Leads for Left Bundle Branch Area Pacing: Materials, Techniques, Benefits, and Trade-Offs of the Two Approaches.Next: LBBAP limits hospital readmissions after TAVR